Lasofoxifene treatment of breast cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11980597
APP PUB NO 20230233490A1
SERIAL NO

18193207

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DUKE UNIVERSITY2812 ERWIN ROAD SUITE 406 DURHAM NC 27705

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andreano, Kaitlyn Durham, US 11 50
Chang, Ching-yi Durham, US 20 85
Gaillard, Stephanie L Durham, US 11 50
McDonnell, Donald P Chapel Hill, US 35 333

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Nov 14, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 14, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 14, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00